DekaBank Deutsche Girozentrale’s Unity Biotechnology UBX Stock Holding History

DekaBank Deutsche Girozentrale’s Portfolio UBX Stock Details UBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-1,300	Closed	-$37K	–	1483
2021 Q3	$37K	Hold	1,300	–	–	﹤0.01%	1343
2021 Q2	$59K	Hold	1,300	–	–	﹤0.01%	1343
2021 Q1	$74K	Hold	1,300	–	–	﹤0.01%	1297
2020 Q4	$67K	Hold	1,300	–	–	﹤0.01%	1292
2020 Q3	$44K	Buy	+1,300	New	+$82.3K	﹤0.01%	1170
2019 Q1	–	Sell	-1,500	Closed	-$252K	–	1255
2018 Q4	$252K	Buy	+1,500	New	+$199K	﹤0.01%	933

Other funds holding UBX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

IFA

Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

DekaBank Deutsche Girozentrale's UBX Position: Q4 2021 in Review

DekaBank Deutsche Girozentrale sold out of Unity Biotechnology (UBX) in Q4 2021, closing a stake of 1,300 shares — an estimated $37K sold.

DekaBank Deutsche Girozentrale first reported a position in UBX in Q4 2018 and held it in 6 quarters. The position peaked at $252K in Q4 2018. 71 funds tracked by Wall St. Rank hold UBX as of Q4 2021.

DekaBank Deutsche Girozentrale reported no remaining Unity Biotechnology position as of Q4 2021 after selling out during the quarter.
DekaBank Deutsche Girozentrale sold 1,300 Unity Biotechnology shares in Q4 2021, an estimated $37K.
DekaBank Deutsche Girozentrale first reported a position in Unity Biotechnology in Q4 2018 and held it in 6 quarters.
DekaBank Deutsche Girozentrale's Unity Biotechnology position peaked at $252K in Q4 2018.
71 funds tracked by Wall St. Rank held Unity Biotechnology as of Q4 2021.

Based on DekaBank Deutsche Girozentrale's 13F filing for Q4 2021, filed 2 Feb 2022.